This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Pharma Stocks With 100% Buy Ratings

6. NuPathe (PATH) is a specialty pharmaceutical company focused on developing and commercializing therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.

For 2010 fourth quarter, analysts polled by Bloomberg expect the company to report a loss of 46 cents per share, compared to loss of $1.01 reported in the quarter-ago period. For the full year, the company is likely to report loss per share of $3.05 for 2010 and $1.73 for 2011, based on analysts' estimates.

The stock has an implied upside of 90% over the next 12 months with a consensus target price of $14.0, according to analysts polled by Bloomberg. In contrast, Pfizer, Merck, Abbott Laboratories, Mylan, Endo Pharmaceuticals and MAP Pharmaceuticals (MAPP) are expected to return around 16%, 17%, 23%, 10%, 15% and 36%, respectively.

All the five analysts covering the stock recommend buying.

6 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
PATH $0.00 0.00%
ATHX $1.33 -1.48%
BDSI $9.14 -0.65%
CPHI $0.39 5.41%
MNOV $4.08 0.00%

Markets

DOW 17,949.59 -85.34 -0.47%
S&P 500 2,097.29 -3.11 -0.15%
NASDAQ 5,014.1020 +19.50 0.39%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs